logo
Plus   Neg
Share
Email

Bouygues Construction To Refurbish Ritz Paris For About €140 Mln - Quick Facts

Bouygues Construction's (BOUYY.PK) unit, Bouygues Bâtiment Île-de-France, has been declared the tender winner for the refurbishment of the celebrated Ritz Hotel, situated in the Place Vendôme in Paris. The luxury hotel is to be totally refitted, which would encompass complete refurbishment of the decoration and renovation of the historic areas, while preserving the spirit of the iconic institution.

The company said that the comfort of guests would be greatly improved by the creation of a summer restaurant with a sliding roof, a larger number of suites, an extension to the ballroom and incorporation of the latest technological innovations. Architect Didier Beautemps of the Atelier Cos firm of architects and interior designer Thierry Despont would coordinate the project, while up to 600 people would be working on-site at peak periods.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
In the age of social media, it takes mere hours for a company to suffer the backlash of of allegations of racism. For some companies, these incidents have hurt their bottom line and sullied their reputations. For others, they were a blip caused by clumsy if not altogether coincidental missteps. In... BJ's Wholesale Club Holdings Inc., which is planning a return to the public market, has set terms for its planned initial public offering or IPO. In a filing with the U.S. Securities and Exchange Commission, the warehouse club operator said Monday that it plans to offer 37.5 million shares priced between $15 and $17 per share. At the top end of the range, the offering would raise $637.5 million. Shares of Valeant Pharmaceuticals International Inc. are falling more than 6 percent in Monday's trading following news that the U.S. Food and Drug Administration has failed to approve the Canada-based company's Duobrii lotion for the treatment of plaque psoriasis. Ortho Dermatologics, a division of Valeant Pharmaceuticals, said it has received a Complete Response Letter or CRL from the FDA.
Follow RTT